Invented by Anthony W. Siadak, Shirley A. Rene, Janine M. Bilsborough, Zymogenetics Inc
The market for polynucleotides encoding IL-31 monoclonal antibodies is experiencing significant growth due to the increasing demand for targeted therapies in the field of immunology. IL-31 monoclonal antibodies have shown promising results in the treatment of various inflammatory and autoimmune diseases, making them a valuable asset in the pharmaceutical industry.
IL-31 is a cytokine that plays a crucial role in the regulation of immune responses and inflammation. It is primarily produced by activated T cells and has been implicated in the pathogenesis of several inflammatory conditions, including atopic dermatitis, asthma, and pruritus. By targeting IL-31, monoclonal antibodies can effectively modulate the immune response and alleviate symptoms associated with these diseases.
The global market for IL-31 monoclonal antibodies is expected to witness substantial growth in the coming years. Factors such as the rising prevalence of chronic inflammatory diseases, increasing healthcare expenditure, and advancements in biotechnology are driving the demand for these targeted therapies. Additionally, the growing awareness among patients and healthcare professionals about the benefits of monoclonal antibody-based treatments is further fueling market growth.
One of the key drivers of the market is the increasing incidence of atopic dermatitis, a chronic inflammatory skin condition characterized by intense itching and eczematous lesions. IL-31 has been identified as a key mediator of pruritus in atopic dermatitis, making it an attractive target for therapeutic intervention. Monoclonal antibodies targeting IL-31 have shown promising results in clinical trials, demonstrating significant reductions in itch severity and improvements in overall disease symptoms.
Another significant factor contributing to market growth is the expanding pipeline of IL-31 monoclonal antibody candidates. Several pharmaceutical companies are actively engaged in the development of novel monoclonal antibodies targeting IL-31, with many candidates currently in various stages of clinical trials. This robust pipeline indicates the growing interest and investment in this therapeutic area, further driving market expansion.
Furthermore, the increasing adoption of personalized medicine and precision therapeutics is expected to propel the market for polynucleotides encoding IL-31 monoclonal antibodies. These therapies offer a targeted approach to treatment, minimizing adverse effects and maximizing therapeutic efficacy. As the understanding of IL-31 biology and its role in various diseases continues to evolve, the demand for personalized IL-31 monoclonal antibody-based therapies is likely to increase.
However, the market for polynucleotides encoding IL-31 monoclonal antibodies is not without challenges. The high cost of monoclonal antibody-based therapies and the stringent regulatory requirements for their approval pose significant barriers to market growth. Additionally, the availability of alternative treatment options and the potential for side effects associated with monoclonal antibody therapy may also hinder market expansion.
In conclusion, the market for polynucleotides encoding IL-31 monoclonal antibodies is witnessing substantial growth due to the increasing demand for targeted therapies in the field of immunology. The potential of IL-31 monoclonal antibodies in the treatment of various inflammatory and autoimmune diseases, coupled with the expanding pipeline of candidates, is driving market expansion. However, challenges such as high costs and regulatory hurdles need to be addressed to fully realize the market’s potential.
The Zymogenetics Inc invention works as follows
The present invention relates primarily to the treatment of pruritic conditions, such as but not limited, to Contact dermatitis (AD), Atopic Dermatitis (AD), Drug-induced delayed type cutaneous allergy reactions, Cutaneous lymphoma, Bullous Pemphigoid (BPL), Vitiligo (Vitiligo), Acne Rosacea(Acne Rosacea), Prurigo nodularis/Sclerodermoderma, Herpes The invention provides hybridomas which generate monoclonal antibody and amino acid sequences for the variable regions in the monoclonal antibody. It also provides chimeric antibodies containing the amino acids sequences from the light and heavy chains variable regions.
Background for Polynucleotides Encoding Il-31 Monoclonal Antibodies
Generation Rat Anti-Mouse MAbs
Generation of Mouse Anti-Human IL-31 mAbs
IL-31RA/OSMRbeta Receptor Luciferase Assay
Luciferase assay on human transformed epithelial cell lines via transient infection with an adenoviral STAT/SRE reporter gene
Inhibition Of Cytokine Production By IL-31Antibodies
Inhibition IL-31 Effects On U937 Monoocyte Adhesion To Transformed Bone Marrow Endothelial (TRBMEC), Monolayer
IL-31 Bioassay Protocol
IL-31 in the Initiation and Maintenance of Contact Hyper-Sensitivity in Vivo
IL-31 Involvement In Atopic Dermatitis in Vivo
Inhibition of itching by administration of Rat Anti-Mouse IL-31 Antibodies”.Click here
to view the patent on Google Patents.